Hello and welcome to the details of AstraZeneca, Nipro sign Covid-19 vaccine deal for supply in Japan and now with the details
Subscribe to our Telegram channel for the latest updates on news you need to know.
TOKYO, May 26 ― AstraZeneca Plc and Nipro Corp signed an agreement to supply the British-Swedish company's Covid-19 vaccine in Japan, Nipro said today.
Tokyo-listed Nipro, a major maker of syringes and medical devices, said the contract was for filling the shot into vials and packaging it, due to start next month. Japan's government has agreed to acquire 120 million doses of AstraZeneca's vaccine, enough for 60 million people.
The shot was officially approved on Friday along with the one developed by Moderna Inc. AstraZeneca already has a deal with Japan's Daiichi Sankyo Co to prepare and bottle doses made from undiluted solution shipped from the United States.
Domestic supply will gradually shift to Japanese producers, with about 90 million doses to be made by JCR Pharmaceuticals Co and other local partners.
Japan started its inoculation drive in mid-February, later than most major economies and using imported doses of the shot developed by Pfizer Inc and BioNTech SE. The Moderna vaccine went into use this week with the opening of mass vaccination centres.
But there are no immediate plans to use AstraZeneca's shot in Japan, amid lingering concerns raised internationally over blood clots. ― Reuters
These were the details of the news AstraZeneca, Nipro sign Covid-19 vaccine deal for supply in Japan for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.